Analyzing Phase I Results of DLL3-Targeted ADC Zocilurtatug Pelitecan in Patients With Small Cell Lung Cancer to Understand the Potential of Next-Generation ADCs in Treating Hard to Treat Cancers
- Demonstrating clinical activity and safety profile of Zocilurtatug Pelitecan
- Discussing the impact this success has on furthering next-generation ADC development
- Identifying the next steps for downstream development